Clinical Trials Browser

Phase 3 × Hematologic Neoplasms × Daunorubicin × Clear all

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms